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Objective: How hexanucleotide (GGGGCC) repeat expansions in C9ORF72 cause amyotrophic lateral sclerosis (ALS)
remains poorly understood. Both gain- and loss-of-function mechanisms have been proposed. Evidence supporting
these mechanisms in vivo is, however, incomplete. Here we determined the effect of C9orf72 loss-of-function in mice.
Methods: We generated and analyzed a conditional C9orf72 knockout mouse model. C9orf72fl/fl mice were crossed
with Nestin-Cre mice to selectively remove C9orf72 from neurons and glial cells. Immunohistochemistry was per-
formed to study motor neurons and neuromuscular integrity, as well as several pathological hallmarks of ALS, such
as gliosis and TDP-43 mislocalization. In addition, motor function and survival were assessed.
Results: Neural-specific ablation of C9orf72 in conditional C9orf72 knockout mice resulted in significantly reduced
body weight but did not induce motor neuron degeneration, defects in motor function, or altered survival.
Interpretation: Our data suggest that C9orf72 loss-of-function, by itself, is insufficient to cause motor neuron dis-
ease. These results may have important implications for the development of therapeutic strategies for C9orf72-
associated ALS.
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A hexanucleotide repeat expansion (GGGGCC) in anoncoding region of C9ORF72 is the most common
genetic cause of amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD; C9ALS/FTD).1–3 Three
possible pathogenic mechanisms have been linked to
C9ORF72 repeat expansions: sequestration of RNA-
binding proteins, toxicity mediated by dipeptides formed
as a result of repeat-associated non-ATG translation, and
haploinsufficiency.1,2,4–6 Experimental evidence support-
ing each of these mechanisms is accumulating.7 However,
how these mechanisms cause ALS/FTD and their rele-
vance in vivo remain poorly understood.
The function of C9ORF72 is not known, but it
has been suggested to play a role in protein trafficking.8,9
Several observations identify C9ORF72 haploinsuffi-
ciency as a hallmark of C9ALS/FTD. First, different
studies report decreased C9ORF72 mRNA expression in
brain tissue, lymphoblast cells, and induced pluripotent
stem cell–derived neurons of patients.1,10,11 Second, one
study shows decreased C9ORF72 protein expression in
frontal cortex of C9ALS/FTD patients.12 Third, knock-
down of C9orf72 in model organisms such as Caeno-
rhabditis elegans and zebrafish embryos causes motor
deficits.10,13 However, knockdown of C9orf72 caused by
The copyright line for this article was changed on 21 August 2015 after original online publication.
View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.24453
Received Mar 10, 2015, and in revised form May 18, 2015. Accepted for publication May 31, 2015.
Address correspondence to Dr Pasterkamp, Department of Translational Neuroscience, Brain Center Rudolf Magnus, UMC Utrecht, Universiteitsweg
100, 3584 CG, Utrecht, the Netherlands. E-mail: r.j.pasterkamp@umcutrecht.nl
From the 1Department of Translational Neuroscience, and 2Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University
Medical Center Utrecht, Utrecht, the Netherlands; and 3Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council
Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, United Kingdom
426 VC 2015 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
a single intracerebroventricular injection of antisense oli-
gonucleotides (ASOs) in mice does not affect motor
function or anxiety.14
To test the haploinsufficiency model and to determine
whether lack of C9orf72 expression leads to motor neuron
degeneration or abnormal motor function, we generated and
analyzed a conditional C9orf72 knockout mouse model.
Materials and Methods
Mouse Husbandry, Breeding, and Genotyping
All animal use and care were in accordance with local institution
guidelines. Mice were kept on a 12-hour light/dark cycle with
food and water available ad libitum. B6;SJL-Tg(ACTFLPe)9205-
Dym/J mice and B6.Cg-Tg(Nes-cre)1Kln/J mice were obtained
from Jackson Laboratory (Bar Harbor, ME; 003800; 003771) and
C57Bl/6J mice from Charles River Laboratories (Wilmington,
MA). To generate C9orf72loxP mice, a targeting construct was
designed to insert an Frt-flanked neomycin cassette and 1 loxP
site upstream of exon 4 and 1 loxP site downstream of exon 5
of C9orf72. Deletion of exons 4 and 5 targets all reported
C9orf72 isoforms in the mouse. This construct was electropo-
rated into C57Bl/6 embryonic stem cells. Correctly targeted
stem cells, as determined by polymerase chain reaction (PCR)
and Southern blot analysis, were injected into blastocysts, and
chimeric mice were bred with C57Bl/6J mice. The resulting
C9orf72loxP-neo mice were then bred with mice expressing Flp
recombinase in their germline to remove the Frt-flanked
neomycin cassette, generating C9orf72loxP/1 offspring. Female
C9orf72loxP/loxP or C9orf72loxP/1 mice were crossed with male
Nestin-Cre1/2;C9orf72loxP mice to generate neural-specific
C9orf72 conditional knockout mice. Mice were genotyped using
primers to detect the Cre gene (forward5 50-GCGGTCTGGC
AGTAAAAACTATC-30, reverse5 5-0GTGAAACAGCATTGC
TGTCACTT-30) and the genomic region containing the loxP
sequences (forward5 50-CCACGGAGGGATGTTCTTTA-30,
reverse5 50-GAAACCAGACCCAAACACAGA-30).
Antibody Generation
The anti-C9orf72 rabbit polyclonal antibody C9-2034 was gen-
erated from an N-terminal thioredoxin fusion of a stretch of 58
amino acids present in all human C9orf72 isoforms comprising
MEDQGQSIIPMLTGEVIPVMELLSSMKSHSVPEEIDIADTVL
NDDDIGDSCHEGFLLK. This was generated from a C9orf72
short isoform expression construct using the primers 50-CCC
GAATTCGAGAGAATGGAAGATCAGGGT-30 and 50-GAAGC
GGCCGCATCTGCTTCATCCAGCTTTTATGA-30. The PCR
product was digested and cloned into the EcoRI/NotI sites of
pET32a (Clontech Laboratories, Mountain View, CA). Thiore-
doxin (Thx)-C9orf72-tail expression was induced in transformed
BL21(DE3) Escherichia coli (Agilent Technologies, Santa Clara,
CA) using 1mM Isopropyl b-D-1-thiogalactopyranoside (IPTG)
for 3 hours at 378C. Thx-C9orf72-Short was purified using His-
Pur resin according to the manufacturer’s instructions (Thermo
Fisher Scientific, Waltham, MA) following solubilization in sonica-
tion buffer (20mM Tris pH 8.0, 100mM NaCl) using a Vibra-
Cell Ultrasonic Processor (Sonics & Materials, Newtown, CT). The
anti-C9orf72 rabbit polyclonal antibody C9-2074 was generated by
reimmunization of the previously described N-terminal thioredoxin
fusion of full-length C9orf72 short isoform.12 The respective puri-
fied fusion proteins were used as antigens for custom rabbit polyclo-
nal antibody generation (Covalab, Villeurbanne, France). Custom
antisera were immunoaffinity-purified against their antigen following
preabsorption against Thx and glial fibrillary acidic protein (Thx-
GFAP expressed in BL21[DE3] transformed with GFAP pET32a).
Both antibodies detected a 50 to 55kDa protein in mouse and
human brain lysates, as well as myc-tagged C9orf72 from transfected
HEK293T cells.
The anti-C9orf72 rabbit polyclonal antibodies were vali-
dated for Western blotting using siRNA-mediated knockdown
of endogenous C9orf72 in HEK293T cells using 27-mer oligo-
nucleotide duplexes as previously described.12 Additional valida-
tion in SH-SY5Y neuroblastoma cells was performed following
knockdown of endogenous C9orf72 using Dicer substrate
RNAi interference using custom dicer substrate siRNA
(DsiRNA; Integrated DNA Technologies, Coralville, IA). Cus-
tom DsiRNA oligonucleotide duplex sequences are C9ORF72-
DsiRNA1F 5-GGAAAGAAUAUGGAUGCAUAAGGAAA-30/
C9ORF72-DsiRNA1R 50-UUUCCUUAUGCAUCCAUAUU
CUUCCUU-30 and C9ORF72-DsiRNA2F 50-GUACUCAAU
GAUGAUGAUAUUGGTG-30/C9ORF72-DsiRNA2R 50-CACC
AAUAUCAUCAUCAUUGAGUACUG-30. The inventoried
FLuc-S1 exogenous reporter gene DsiRNA duplex was used as a
nontargeting control. DsiRNAwas transfected using the same condi-
tions as 27mer oligonucleotide duplexes. Whole cell and tissue lysate
preparation andWestern blotting were performed as described previ-
ously.12 Western blotting using the anti-C9orf72 rabbit polyclonal
antibodies detected no C9orf72 expression in knockout mice (Fig 1)
or reduced expression following knockdown of C9orf72 (in
HEK293 or SHSY5Y cells; data not shown).
In Situ Hybridization
Fresh frozen mouse embryos, or spinal cord and brain tissue
from adult mice were cut at 16 to 20mm on a cryostat. Nonra-
dioactive in situ hybridization was performed as described pre-
viously.15 A digoxigenin-labeled C9orf72 probe was transcribed
from mouse cDNA (a 736bp fragment corresponding to nucle-
otides 298–1,034 of 3110043O21Rik) using a DIG RNA label-
ing SP6/T7 kit (Roche, Basel, Switzerland). Sense probes were
used to confirm specificity. Images were taken on a Zeiss
(Oberkochen, Germany) AxioSkop2 microscope.
Quantitative Real-Time PCR
Fresh frozen tissue was homogenized in TRIzol reagent and total
RNA was isolated. After DNAse treatment, cDNA was synthesized
using superscript II reverse transcriptase (Life Technologies, Carlsbad,
CA) and oligo-dT primers. Quantitative real-time PCR was per-
formed using SYBR green reagent (Roche) on a QuantStudio 6 Flex
real-time PCR system (Applied Biosystems, Foster City, CA) using
primers against 3110043O21Rik (Q1 [exon 2]: forward5 50-
GACCTGGAATGCAGTGAGAC-30, reverse5 50-TCCCAGTAA
GCAAAGGTAGC; Q2 [exons 3–6]: forward5 50-GGCACAGA
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GAGGATGGAAGA-30, reverse5 50-CTGCCAACTACAACGG
AACA-30; Q3 [exons 6–8]: forward5 50-TGGCTGTTCCGTTGT
AGTTG-30, reverse5 50-AACTGCCTGTTGCATCCTTT-30; Q4
[exons 7–8]: FW5 50-GTACGAATCGGGACTCTTTG-30,
reverse5 50-GCTTGACAGTGTTGACATCC-30; Q5 [exons 8–9]:
forward5 50-CAACGCAGATACATGAGGTC-30, reverse5 50-
GGAAGGCTTTCACTAGAGTGTC-30; Q6 [exons 10–11]:
forward5 50-CCCTTTAAGTCTCTTCGGAACC-30, reverse5
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50-AGACAGACACAGCAAACCAC-30) and mRNA levels were
normalized to Gapdh (forward5 50-GAGACGGCCGCATCTT
CTTGT-30, reverse5 5-0 CACACCGACCTTCACCATTTT-30)
and Tbp (QT00198443; Qiagen, Valencia, CA) housekeeping genes.
Samples from 3 mice per genotype were amplified in triplicate, and
relative quantification using comparative DDCT values was statically
analyzed using Student t test.
Western Blotting
Western blotting was performed as described previously.16 In
brief, fresh frozen tissue was homogenized in radioimmunopre-
cipitation assay buffer (50mM Tris pH 7.6, 150mM NaCl,
0.5mM ethylenediaminetetraacetic acid, 1% sodium deoxycho-
late, 0.1% sodium dodecyl sulfate, 1% Triton-X-100, and pro-
tease inhibitor cocktail), centrifuged twice at 10,000 3 g, and
the supernatant was used as total protein. Western blotting was
performed using 50mg of total protein per lane as measured by
bicinchoninic acid assay (Pierce Biotechnology, Rockford, IL),
and blots were probed with the following antibodies: anti-
C9orf72 (2034; 1:250), anti-C9orf72 (2074; 1:250), and
anti–b-actin (Sigma, St Louis, MO; 1:2,000). After overnight
incubation, blots were probed with horseradish peroxidase–
conjugated secondary antibodies and developed with SuperSignal
West Femto chemiluminescent substrate (Pierce Biotechnology).
Motor Function Testing
Mice were weighed and tested for their hindlimb extension
reflex weekly. Every 3 weeks, mice performed 5 trials on an
accelerating rotarod (Ugo Basile, Varese, Italy) at 4rpm with an
acceleration of 0.2rpm/s for 180 seconds and the latency to fall
was recorded. Mice that rotated passively were scored as fallen.
Grip strength of front paws and of front and hind paws
together was measured every 3 months using a grip strength
meter (Bioseb, Vitrolles, France). Strength was measured 5
times for each mouse both for front and for front and hind
paws. All behavioral tests were performed on 11 mice per
genotype for each time point. Statistical analysis was carried out
using R software (http://www.r-project.org). (Non-)linear mixed
models were used to account for repeated measurements and
other sources of correlation within the longitudinal data and to
provide a correct model in case of missing data. For statistical
analysis of body weight, a nonlinear mixed effects model was
used with gender as a covariate. Interactions between time and
behavioral tests were analyzed to study possible changes during
follow-up. For rotarod and grip strength statistical analysis, a
nonlinear mixed effects model was used with gender and body
weight as covariates. Survival analysis was carried out using a
Cox regression analysis with mean body weight as covariate.
Cox proportional hazard assumptions were tested.
Immunohistochemistry
Immunohistochemistry was performed as described previously.17
Tissues were removed and cryoprotected in 30% sucrose after
transcardial perfusion with 4% paraformaldehyde. Spinal cord
and brain were cut at 20mm and mounted on SuperFrost Plus
slides (Thermo Fisher Scientific). For immunofluorescent stain-
ings, sections were blocked and incubated overnight at 48C
with the following antibodies: anti-GFAP (Dako, Carpinteria,
CA), anti-Iba1 (Wako Chemicals, Richmond, VA), anti–choline
acetyltransferase (ChAT; Millipore, Billerica, MA), and anti–
TDP-43 (Proteintech, Chicago, IL). Alexa Fluor–conjugated
secondary antibodies were incubated for 2 hours at room tem-
perature (RT) and 40,6-diamidino-2-phenylindole was used to
stain nuclei. For diaminobenzidine (DAB) stainings, sections
were incubated overnight at 48C with anti-ubiquitin antibodies
(Millipore) and for 1 h at RT with goat anti-mouse biotin.
Slides were incubated with ABC reagent (Vector Laboratories,
Burlingame, CA) for 1 h and developed with DAB reagent
(Sigma). For motor neuron counting, at least 10 spinal cord
sections (L1–L6) per mouse using 3 mice per genotype were
analyzed and only ChAT-positive neurons with a clear nucleus
were counted and measured. For GFAP and Iba1 quantifica-
tion, at least 10 spinal cord sections (L1–L6) from 3 mice per
genotype were analyzed for positive staining area using ImageJ
(NIH, Bethesda, MD). For neuromuscular junction staining,
gastrocnemius muscle was cut longitudinally at 40mm and
stained with anti–a-bungarotoxin-488 (Life Technologies), anti-
sv2 (Developmental Studies Hybridoma Bank [DSHB], Iowa
FIGURE 1: Expression of C9orf72 and generation of C9orf72 conditional knockout mice. (A–G) In situ hybridization shows
expression of C9orf72 in coronal sections of the adult brain and spinal cord. (F, G) Double staining combining in situ hybridiza-
tion for C9orf72 and immunohistochemistry for SMI132, a marker for motor neurons (indicated by arrowheads). (E, M) Sections
incubated with sense probes do not display specific staining. (H–O) At embryonic and early postnatal stages, C9orf72 is
expressed in spinal cord motor neurons (arrowheads in H–J), the retina, olfactory system, and other brain regions, in addition
to non-neuronal tissues such as kidney. (P) Schematic representation of the C9orf72 targeting vector, targeted allele, floxed
allele following Flp recombination, and deleted allele following Cre recombination. Black arrows indicate transcription start
site, gray arrows indicate location of loxP primers (P1, P2), and numbers indicate exons. Please note that exons 4 and 5 are
shared by all 3 reported mouse C9orf72 isoforms. (Q) Genotyping using loxP primers on DNA isolated from ear and brain
tissue of Nestin-Cre1/2;C9orf721/1 and Nestin-Cre1/2;C9orf72fl/fl mice shows brain-specific recombination. (R) Quantitative
real-time polymerase chain reaction shows tissue-specific reduction of C9orf72 levels in Nestin-Cre1/2;C9orf72fl/1 and/or
Nestin-Cre1/2;C9orf72fl/fl in brain (0.493, p50.0004 and 0.044, p50.00007) and spinal cord (0.684, p50.083 and 0.145,
p50.002), but not in muscle (0.789, p50.594 and 0.585, p50.169) or liver (1.94, p50.219 and 1.74, p50.473). Results are
shown with Tbp as a housekeeping gene. Data are presented as mean6 standard deviation, n53 for each genotype. (S) In
situ hybridization for C9orf72 shows loss of C9orf72 expression in spinal cord of Nestin-Cre1/2;C9orf72fl/fl mice. **p<0.01,
***p<0.001. CA15 cornu ammonis 1; Cx5 cortex; DG5dentate gyrus; DRG5dorsal root ganglia; F5Frt site; GL5granular
cell layer; GM5gray matter; L5 loxP site; Mol5molecular layer; N5neomycin cassette; OE5olfactory epithelium;
P15 forward loxP primer; P25 reverse loxP primer; Ret5 retina; RN5 red nucleus; VNO5 vomeronasal organ; WM5white
matter; WT5wild type. Scale bars: A, 200lm; H, 100lm; K, 100lm, S, 150lm.
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City, IA), and anti-neurofilament (DSHB) antibodies. At least
150 neuromuscular junctions were counted per mouse. Images
were taken on an Olympus (Tokyo, Japan) FluoView FV1000
confocal microscope or a Zeiss AxioScope microscope followed
by image analysis using ImageJ. Statistical analysis was performed
using Student t test (SPSS Statistics; IBM, Armonk, NY).
Results
Genetic Ablation of C9orf72 in Mice
Previous work analyzing C9orf72-LacZ knockin mice
reported C9orf72 expression in neurons known to degen-
erate in ALS and FTD, such as cortical and spinal cord
motor neurons.18 To confirm and extend these findings,
we performed in situ hybridization for the mouse
C9orf72 orthologue, 3110043O21Rik (here referred to as
C9orf72), at embryonic, postnatal, and adult stages. As
reported previously, neuronal C9orf72 expression was
detected in several regions of the adult brain and spinal
cord (see Fig 1; Table).18 In contrast to previous work,
however, prominent expression of C9orf72 was also
observed in embryonic and early postnatal neurons.
These included retinal ganglion cells, sensory neurons in
the olfactory epithelium and in dorsal root ganglia, and
spinal motor neurons. In addition, expression in non-
neuronal tissues such as kidney and tooth was detected.
These results indicate that C9orf72 may also function
during embryonic and postnatal development.
To circumvent problems such as embryonic lethal-
ity, we generated conditional C9orf72 knockout mice
using the Cre-loxP system and bred the resulting
TABLE. Overview of C9orf72 Expression in the Developing Mouse Embryo and Adult Central
Nervous System
Location E13.5 E15.5 E17.5 P1 P15 Adult
Brain
Cortex 1 1 1 1 11 1
Hippocampal formation 1 1 11 11 11 11
Dentate gyrus N/D N/D 11 11 11 11
Cornu ammonis N/D N/D 11 11 11 11
Thalamus N/D N/D N/D 1 11 1
Midbrain/pons N/D 1 1 1 11 11
Ventral tegmental area N/D N/D N/D 2 2 2
Pontine nuclei N/D N/D N/D 1 11 11
Red nucleus N/D N/D N/D 1 11 11
Facial motor nucleus N/D N/D N/D 1 11 11
Cerebellum 1 1 1 1 1 1
Molecular layer N/D N/D N/D 1 1 1
Granule cell layer N/D N/D N/D 1 1 1
Spinal cord
Gray matter 11 11 11 11 11 11
White matter 2 2 2 2 2 2
Dorsal root ganglia 11 11 11 11 11 11
Other
Eye 11 11 11 11 N/D N/D
Olfactory epithelium 11 11 11 11 N/D N/D
Tooth 11 11 11 11 N/D N/D
Kidney 1 1 1 1 N/D N/D
N/D5 not determined, 25 no expression,1 = weak expression, 115moderate/strong expression.
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C9orf72fl/fl mice to Nestin-Cre mice (see Fig 1). In
Nestin-Cre mice, Cre recombination occurs in neuronal
and glial precursors from E10.5 onward.19 The specific
ablation of C9orf72 mRNA and protein in Nestin-Cre1/2;
C9orf72fl/fl mice was confirmed using different approaches.
First, DNA genotyping on ear clips or brain tissue showed
excision of exons 4 and 5 only in brain tissue. Second, quanti-
tative real-time PCR detected a reduction in C9orf72 mRNA
levels in brain and spinal cord tissue but not in other tissues
of Nestin-Cre1/2;C9orf72fl/fl mice. Third, in situ hybridiza-
tion detected C9orf72 in the spinal cord of Nestin-Cre1/2;
C9orf721/1 but not inNestin-Cre1/2;C9orf72fl/flmice.
Three C9orf72 isoforms have been reported in
mice. These isoforms all contain exons 4 and 5 and are
FIGURE 2: Cre-mediated excision of C9orf72 affects all C9orf72 isoforms. (A) Schematic overview of the 3 reported mouse
C9orf72 isoforms. Q1 to Q6 indicate regions amplified by quantitative real-time polymerase chain reaction (qPCR). The in situ
probes used are indicated. Dotted lines indicate antigen regions used to generate the 2 anti-C9orf72 antibodies (C9-2034 and
C9-2074). (B) Amino acid sequence of the antigen used to generate the novel anti-C9orf72 antibody C9-2034, and its compari-
son to human C9ORF72 isoforms and mouse C9orf72 isoforms. (C) qPCR using primers that target different exonic regions
shared by 1 or multiple mouse isoforms shows a significant reduction of brain C9orf72 mRNA levels in Nestin-Cre1/2;C9orf72fl/1
and/or Nestin-Cre1/2;C9orf72fl/fl mice. Results are shown using Tbp as a housekeeping gene. Data are presented as
mean6 standard deviation, n52 for each genotype. (D)Western blot analysis of whole brain lysates using 2 different anti-C9orf72 anti-
bodies shows a ~55kDa band in control mice that is reduced or absent in Nestin-Cre1/2;C9orf72fl/1 or Nestin-Cre1/2;C9orf72fl/fl mice,
respectively. Note that only isoform 1 is detected at the protein level in mouse brain. b-Actin was used as a loading control.
***p<0.001. L5 loxP sites.
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targeted in the C9orf72 conditional knockout mouse (Fig
2). To confirm that the expression of all isoforms is
affected by the excision of exons 4 and 5, we performed
quantitative real-time PCR to detect expression of differ-
ent exonic regions present in 1 or multiple isoforms. As
expected, a reduction of C9orf72 mRNA levels was
found for all exonic regions analyzed. In addition, we
generated a new anti-C9orf72 antibody. This antibody
was raised against a 58 amino acid stretch shared by all
isoforms (C9-2034). The other antibody used was
reported previously and was raised using a large part of
the C9orf72 protein. The region used is present in 2 of
the 3 isoforms (C9-2074).12 Western blotting using these
antibodies showed a predicted 55kDa band, corre-
sponding to isoform 1, that was lost in brain tissue of
Nestin-Cre1/2;C9orf72fl/fl mice. The other 2 C9orf72 iso-
forms (isoforms 2 and 3) were not detected in wild-type
mouse brain tissue (data not shown). Together, these
results confirm the neural-specific and successful ablation
of C9orf72 in Nestin-Cre1/2;C9orf72fl/fl mice.
Mice Lacking C9orf72 in Neurons and Glial
Cells Do Not Display Motor Neuron
Degeneration or Defects in Motor Function
ALS is characterized by progressive motor neuron degen-
eration and a decline in motor performance. To examine
a possible role for C9orf72 haploinsufficiency in ALS
pathogenesis, we therefore assessed motor function,
motor neuron number, and neuromuscular integrity in
12-month-old (data not shown) and 18-month-old
Nestin-Cre1/2;C9orf72fl/fl mice and littermate controls.
Nestin-Cre1/2;C9orf72fl/fl mice were born at the expected
Mendelian ratio and were indistinguishable from Nestin-
Cre1/2;C9orf721/1 control littermates in viability,
appearance, fertility, and the gross anatomical and histo-
logical appearance of the brain. Immunohistochemistry
for ChAT, to visualize spinal motor neurons, did not
reveal changes in neuron number or size (Fig 3A, B).
Furthermore, innervation of the gastrocnemius muscle by
motor axons, as assessed by overlap between the pre- and
postsynaptic compartment of the neuromuscular junc-
tion, was similar in Nestin-Cre1/2;C9orf72fl/fl mice and
controls (see Fig 3C, D). Astro- and microgliosis are hall-
marks of ALS. However, no differences in immunostaining
for GFAP or Iba1, to label astrocytes or microglia, respec-
tively, were detected between spinal cord or brain tissue from
Nestin-Cre1/2;C9orf72fl/fl mice and littermate controls (Figs
4A–D, 5A–F00, 6A–F00). Similarly, other hallmarks of ALS
pathogenesis, such as TDP-43 mislocalization or changes in
ubiquitin staining, were absent in Nestin-Cre1/2;C9orf72fl/fl
mice (see Figs 4E–H, 7). Similar results were obtained in
12-month-oldNestin-Cre1/2;C9orf72fl/flmice, that is, absence
FIGURE 3: Neural-specific ablation of C9orf72 does not
cause changes in motor neuron number, size, or neuromus-
cular junction (NMJ) connectivity in 18-month-old Nestin-
Cre1/2;C9orf72fl/fl mice. (A, B) Immunofluorescent staining
of adult spinal cord using anti–choline acetyltransferase
(ChAT) antibodies. Graphs show quantification of motor
neuron number and size. Dotted lines indicate border
between gray matter (GM) and white matter (WM). (C, D)
Representative images of NMJs in gastrocnemius muscle
visualized by immunohistochemistry for neurofilament (NF)
and synaptic vesicle protein 2 (SV2) in combination with
Alexa Fluor 488–conjugated bungarotoxin (BTX) binding.
Graph shows overlap between presynaptic (gray arrowhead)
and postsynaptic staining (white arrowhead). Motor neurons
and their NMJs are intact in Nestin-Cre1/2;C9orf72fl/fl mice.
Data in graphs represent mean6 standard deviation, n53
per genotype. Scale bars: A, 100lm; C, 30lm. DAPI540,6-
diamidino-2-phenylindole.
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of defects in motor neuron number, size, and connectivity
and no signs of gliosis or other pathological hallmarks of ALS
(data not shown). Thus, C9orf72 deficiency in mice fails to
cause several of the pathological hallmarks reported in ALS
patients or mouse models.
A reduction in body weight was detected in all
Nestin-Cre–positive mice, as has been previously reported
for other studies using this Cre driver.20 However, even
when considering this effect, Nestin-Cre1/2;C9orf72fl/fl
mice displayed a small but significant decrease in body
weight, as compared to Nestin-Cre1/2;C9orf721/1 con-
trol mice (26.02%, p5 0.019). This difference was
detected at the first time point of measurements and did
not significantly change in time (Fig 8). To assess motor
performance, the hindlimb extension reflex was tested
(data not shown) and mice were assessed using an acceler-
ating rotarod and a grip strength meter for a period of 18
months after birth. No differences in motor performance
or grip strength were found between Nestin-Cre1/2;
C9orf72fl/fl mice and various control mice. A similar result
was obtained in a smaller cohort of 2-year-old mice
(n 4; data not shown). Finally, survival was not signifi-
cantly altered in Nestin-Cre1/2;C9orf72fl/fl mice, the oldest
mice living >24 months. Thus, Nestin-Cre1/2;C9orf72fl/fl
FIGURE 4: Neural-specific ablation of C9orf72 does not cause signs of neuroinflammation or other pathological hallmarks of
amyotrophic lateral sclerosis in 18-month-old Nestin-Cre1/2;C9orf72fl/fl mice. (A–D) Immunofluorescent staining of adult spinal
cord using anti–glial fibrillary acidic protein (GFAP) or anti-Iba1 antibodies. Graphs show quantification of GFAP- or Iba1-
positive areas. No signs of gliosis are observed in Nestin-Cre1/2;C9orf72fl/fl mice. (E, F) Immunofluorescent staining of adult
spinal cord using anti–TDP-43 antibodies. Nuclear TDP-43 staining is detected in Nestin-Cre1/2;C9orf72fl/fl mice and control lit-
termates. (G, H) Representative images showing immunostaining for ubiquitin in adult spinal cord. Ubiquitin expression is not
affected by loss of C9orf72. Data in graphs represent mean6 standard deviation, n53 per genotype. Scale bars: A, C, G,
100lm; E, 30lm. DAPI540,6-diamidino-2-phenylindole; GM5gray matter; WM5white matter.
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mice do not display overt defects in motor function or
decreased survival.
Discussion
C9orf72 haploinsufficiency may contribute to the patho-
genic mechanism in C9ALS/FTD patients. To test this
hypothesis, we generated a conditional C9orf72 knockout
mouse model. Two previous studies have reported the
generation of C9orf72 knockout mice, but neither study
provided a histological or behavioral characterization.18,21
In one of these studies, using C9orf72-LacZ knockin re-
porter mice, C9orf72 expression was not detected at
embryonic and early postnatal stages in the mouse.18 In
contrast, we show neuronal C9orf72 expression at several
sites in the embryonic nervous system, as well as in non-
neuronal tissues. This observation is in line with a recent
study showing expression of C9orf72 both inside and
outside the nervous system of zebrafish embryos.10 The
cause of this apparent discrepancy is unknown but may
include the inability of heterozygous LacZ reporter mice
FIGURE 5: Immunostaining for glial fibrillary acidic protein (GFAP) in the brain of 18-month-old mice. Immunofluorescent stain-
ing is shown for GFAP in frontal cortex, motor cortex, and hippocampus of Nestin-Cre1/2;C9orf721/1 mice (A–C00) and Nestin-
Cre1/2;C9orf72fl/fl mice (D–F00). Boxes in A–C and D–F are shown at higher magnification in A0–C00 and D0–F00, respectively. No
changes in the distribution, number, or appearance of GFAP-positive astrocytes were detected in Nestin-Cre1/2;C9orf72fl/fl
mice. Scale bars: A, D, 200lm; A0, D0, 100lm. DAPI540,6-diamidino-2-phenylindole.
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to detect low levels of gene expression.22 Together, our
data suggest that C9orf72 plays a role during embryonic
and postnatal development.
The expression of C9orf72 at embryonic stages and
in several tissues outside the nervous system prompted us
to selectively ablate C9orf72 in neurons and glial cells by
crossing C9orf72fl/fl mice with Nestin-Cre mice. The
resulting Nestin-Cre1/2;C9orf72fl/fl mice did not show
overt defects in motor function or pathological hallmarks
of ALS, such as reduced motor neuron number, gliosis,
TDP-43 mislocalization, or enhanced ubiquitination. A
small but significant decrease in body weight was found
in Nestin-Cre1/2;C9orf72fl/fl mice. Our results are in
apparent contrast with recent work in model organisms
such as zebrafish and C. elegans. Knockdown or knock-
out, respectively, of C9orf72 orthologues in zebrafish and
C. elegans causes motor deficits. These include age-
dependent motility defects and c-aminobutyric acidergic
motor neuron degeneration in C. elegans, and motor
axon and behavior deficits in zebrafish.10,13 The discrep-
ancy with our results may be caused by the low homol-
ogy of C9orf72 orthologues in humans and in zebrafish
FIGURE 6: Immunostaining for Iba1 in the brain of 18-month-old mice. Immunofluorescent staining is shown for Iba1 in frontal
cortex, motor cortex, and hippocampus of Nestin-Cre1/2;C9orf721/1 mice (A–C00) and Nestin-Cre1/2;C9orf72fl/fl mice (D–F00).
Boxes in A–C and D–F are shown at higher magnification in A0–C00 and D0–F00, respectively. No changes in the distribution, num-
ber, or appearance of Iba1-positive microglia are detected in Nestin-Cre1/2;C9orf72fl/fl mice. Scale bars: A,D, 200lm; A0, D0,
100lm. DAPI540,6-diamidino-2-phenylindole.
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and C. elegans (76% and 23% compared to human
C9ORF72, respectively) as compared to the high homology
between human and mouse C9orf72 (98%). Another possi-
ble explanation could be redundancy of the C9orf72 gene
in mammalian species. In line with our results, a single
treatment of wild-type mice with ASOs directed against
C9orf72 did not lead to motor abnormalities.14
Together, our data suggest that loss of C9orf72 on its
own is insufficient to cause ALS. Our results, however, do
not rule out the possibility that C9ORF72 loss-of-function
FIGURE 7: Immunostaining for TDP-43 and ubiquitin in several brain regions of 18-month-old mice. (A–C, G–I) Immunofluores-
cent staining of adult spinal cord using anti–TDP-43 antibodies is shown. Nuclear TDP-43 staining is detected in Nestin-Cre1/2;
C9orf72fl/fl mice and control littermates. (D–F, J–L) Representative images show immunostaining for ubiquitin in adult spinal
cord. Ubiquitin expression is not affected by loss of C9orf72. DAPI540,6-diamidino-2-phenylindole; GCL5granule cell layer;
H5hilus. Scale bars560lm.
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modulates the disease process and influences disease onset,
severity, and duration in C9ALS/FTD patients. The dis-
ease mechanisms caused by repeat expansions in
C9ORF72 are likely to be complex and may ultimately
result from interplay between C9ORF72 loss- and gain-of-
function mechanisms.23,24 In support of a gain-of-function
mechanism, recent work shows that AAV-mediated expres-
sion of 66 GGGGCC repeats in the adult mouse brain
induces key features of ALS/FTD, such as TDP-43 pathol-
ogy and behavioral deficits.6 A different study, using trans-
genic mice with inducible expression of hexanucleotide
(GGGGCC) repeats, found ubiquitinated inclusions, but
these inclusions were not detected in neuronal populations
relevant for ALS/FTD and no motor phenotype was
found.25 Our finding that loss of C9orf72 function does
not lead to motor neuron disease in mice has consequences
for therapeutic strategies, because it indicates that ASOs
directed at the repeat expansion that also lower C9ORF72
expression are unlikely to have negative side effects due to
reduced C9ORF72 expression.
FIGURE 8: Loss of C9orf72 in mice does not affect motor function and survival. (A) A small decrease in body weight is detected
in Nestin-Cre1/2;C9orf72fl/fl mice as compared to Nestin-Cre1/2;C9orf721/1 controls (26.02%, p50.019, linear mixed-effect
model for repeated measurements [LME]; n11 for each genotype at each time point). (B–D) Rotarod performance and grip
strength is similar in Nestin-Cre1/2;C9orf721/1, Nestin-Cre1/2;C9orf72fl/1, and Nestin-Cre1/2;C9orf72fl/fl mice (rotarod,
p50.084 and p50.899; grip strength front, p50.346 and p50.295; front and hind, p50.731 and p50.305, LME). Data are
shown as mean6 standard deviation, n11 for each genotype at each time point. (E) Survival rates as shown by a Kaplan–
Meier curve. Survival of Nestin-Cre1/2;C9orf72fl/fl mice is similar to control mice.
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